Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study
Sign Up to like & getrecommendations! Published in 2020 at "Lung"
DOI: 10.1007/s00408-020-00379-6
Abstract: Benralizumab and mepolizumab are new therapies for severe eosinophilic asthma. They are both humanized IgG antibodies, targeting the IL‐5 receptor and IL‐5, respectively, suppressing the corresponding pathways. No specific biomarkers have been proposed to evaluate… read more here.
Keywords: eosinophilic asthma; mepolizumab benralizumab; severe eosinophilic; proteomic study ... See more keywords
Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab
Sign Up to like & getrecommendations! Published in 2020 at "International Archives of Allergy and Immunology"
DOI: 10.1159/000508936
Abstract: Background: New anti-IL-5 antibodies, mepolizumab and benralizumab, have recently been approved for severe asthma, sharing the same inclusion criteria. Objective: To contribute on biomarkers research leading to the personalized choice, we investigated L-selectin, Krebs von… read more here.
Keywords: mepolizumab benralizumab; severe eosinophilic; personalized approach; patients treated ... See more keywords
Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study
Sign Up to like & getrecommendations! Published in 2022 at "Internal Medicine"
DOI: 10.2169/internalmedicine.8180-21
Abstract: Objective Switching from mepolizumab to benralizumab has been reported to significantly improve both asthma control and the lung function. However, the data on its efficacy in elderly patients with severe eosinophilic asthma are limited. This… read more here.
Keywords: eosinophilic asthma; elderly patients; asthma; severe eosinophilic ... See more keywords